Neurocrine biosciences supports the mental health community during tardive dyskinesia awareness week

Approximately 600,000 people in the united states live with tardive dyskinesia (td), and nearly seven out of 10 people living with the condition have not yet been diagnosed1,2 san diego , may 1, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its continued support of increasing awareness regarding the prevalence, impact and importance of screening for tardive dyskinesia (td), during tardive dyskinesia awareness week, may 1-7. td is an involuntary movement disorder associated with prolonged use of certain mental health medicines (antipsychotics) that can be used to treat bipolar disorder, depression, schizophrenia and schizoaffective disorder.1,3,4 experience the full interactive multichannel news release here: https://www.multivu.com/players/english/9147351-neurocrine-biosciences-tardive-dyskinesia-awareness-week/ this year marks the sixth consecutive year the mental health advocacy community, states across the country and washington, d.c.
NBIX Ratings Summary
NBIX Quant Ranking